Chronic obstructive pulmonary disease (COPD) is significant cause of morbidity and mortality worldwide. There is mounting evidence suggesting that COPD patients are at increased risk of severe COVID-19 outcomes; however, it remains unclear whether they are more susceptible to acquiring SARS-CoV-2 infection. In this comprehensive review, we aim to provide an up-to-date perspective of the intricate relationship between COPD and COVID-19. We conducted a thorough review of the literature to examine the evidence regarding the susceptibility of COPD patients to COVID-19 infection and the severity of their disease outcomes. While most studies have found that pre-existing COPD is associated with worse COVID-19 outcomes, some have yielded conflicting results. We also discuss confounding factors such as cigarette smoking, inhaled corticosteroids, and socioeconomic and genetic factors that may influence this association. Furthermore, we review acute COVID-19 management, treatment, rehabilitation, and recovery in COPD patients and how public health measures impact their care. In conclusion, while the association between COPD and COVID-19 is complex and requires further investigation, this review highlights the need for careful management of COPD patients during the pandemic to minimize the risk of severe COVID-19 outcomes.

1. Ackermann, M., Verleden, S. E., Kuehnel, M., Haverich, A., Welte, T., Laenger, F., Vanstapel, A., Werlein, C., Stark, H., Tzankov, A., Li, W. W., Li, V. W., Mentzer, S. J., & Jonigk, D. (2020). Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. New England Journal of Medicine, 383(2), 120–128. https://doi.org/10.1056/NEJMoa2015432
2. Aleva, F. E., Voets, L. W. L. M., Simons, S. O., de Mast, Q., van der Ven, A. J. A. M., & Heijdra, Y. F. (2017). Prevalence and localization of pulmonary embolism in unexplained acute exacerbations of COPD: A systematic review and meta-analysis. Chest, 151(3), 544–554. https://doi.org/10.1016/j.chest.2016.07.034
3. Alhazzani, W., Møller, M. H., Arabi, Y. M., Loeb, M., Gong, M. N., Fan, E., Oczkowski, S., Levy, M. M., Derde, L., Dzierba, A., Du, B., Aboodi, M., Alshamsi, F., Alshahrani, M. S., Al-Omari, A., Al Fares, A., Al-Hameed, F., Al-Khafaji, A., Al-Moamary, M., . . . Rhodes, A. (2020). Surviving Sepsis Campaign: Guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Critical Care Medicine, 48(6), e440–e469. https://doi.org/10.1097/CCM.0000000000004363
4. Alkhathami, M. G., Advani, S. M., Abalkhail, A. A., Alkhathami, F. M., Alshehri, M. K., Albeashy, E. E., & Alsalamah, J. A. (2021). Prevalence and mortality of lung comorbidities among patients with COVID-19: A systematic review and meta-analysis. Lung India, 38(7), S31–S40. https://doi.org/10.4103/lungindia.lungindia_693_20
5. Almeida Monteiro, R. A., de Oliveira, E. P., Nascimento Saldiva, P. H., Dolhnikoff, M., Duarte-Neto, A. N., & BIAS—Brazilian Image Autopsy Study Group. (2020). Histological-ultrasonographical correlation of pulmonary involvement in severe COVID-19. Intensive Care Medicine, 46(9), 1766–1768. https://doi.org/10.1007/s00134-020-06194-w
6. Asrani, P., Eapen, M. S., Chia, C., Haug, G., Weber, H. C., Hassan, M. I., & Sohal, S. S. (2021). Diagnostic approaches in COVID-19: Clinical updates. Expert Review of Respiratory Medicine, 15(2), 197–212. https://doi.org/10.1080/17476348.2021.1823221
7. Asrani, P., Eapen, M. S., Hassan, M. I., & Sohal, S. S. (2021). Implications of the second wave of COVID-19 in India. The Lancet Respiratory Medicine, 9(9), e93–e94. https://doi.org/10.1016/S2213-2600(21)00312-X
8. Asrani, P., Hasan, G. M., Sohal, S. S., & Hassan, M. I. (2020). Molecular basis of pathogenesis of coronaviruses: A comparative genomics approach to planetary health to prevent zoonotic outbreaks in the 21st century. Omics: A Journal of Integrative Biology, 24(11), 634–644. https://doi.org/10.1089/omi.2020.0137
9. Asrani, P., Tiwari, K., Eapen, M. S., Hassan, M. D. I., & Sohal, S. S. (2022). Containment strategies for COVID-19 in India: Lessons from the second wave. Expert Review of Anti-infective Therapy, 20(6), 829–835. https://doi.org/10.1080/14787210.2022.2013812
10. Asrani, P., Tiwari, K., Eapen, M. S., McAlinden, K. D., Haug, G., Johansen, M. D., Hansbro, P. M., Flanagan, K. L., Hassan, M. I., & Sohal, S. S. (2022). Clinical features and mechanistic insights into drug repurposing for combating COVID-19. The International Journal of Biochemistry & Cell Biology, 142, Article 106114. https://doi.org/10.1016/j.biocel.2021.106114
11. Asselta, R., Paraboschi, E. M., Mantovani, A., & Duga, S. (2020). ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy. Aging, 12(11), 10087–10098. https://doi.org/10.18632/aging.103415
12. Atto, B., Eapen, M. S., Sharma, P., Frey, U., Ammit, A. J., Markos, J., Chia, C., Larby, J., Haug, G., Weber, H. C., & Sohal, S. S. (2019). New therapeutic targets for the prevention of infectious acute exacerbations of COPD: Role of epithelial adhesion molecules and inflammatory pathways. Clinical Science, 133(12), 1663–1703. https://doi.org/10.1042/CS20180905
13. Aveyard, P., Gao, M., Lindson, N., Hartmann-Boyce, J., Watkinson, P., Young, D., Coupland, C. A. C., Tan, P. S., Clift, A. K., Harrison, D., Hippisley-Cox, J., & Khunti, K. (2021). Association between pre-existing respiratory disease and its treatment, and severe COVID-19: A population cohort study. The Lancet Respiratory Medicine, 9(8), 909–923. https://doi.org/10.1016/S2213-2600(21)00095-3
14. Bartoletti, M., Giannella, M., Scudeller, L., Tedeschi, S., Rinaldi, M., Bussini, L., Fornaro, G., Pascale, R., Pancaldi, L., Pasquini, Z., Gianpure, S., Giaquinto, E., Marconi, L., Ambretti, S., Lewis, R. E., & Viale, P. (2020). Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: A multicentre cohort study (PREDI-CO study). Clinical Microbiology and Infection, 26(11), 1545–1553. https://doi.org/10.1016/j.cmi.2020.08.003
15. Barton, L. M., Duval, E. J., Stroberg, E., Ghosh, S., & Mukhopadhyay, S. (2020). COVID-19 autopsies, Oklahoma, USA. American Journal of Clinical Pathology, 153(6), 725–733. https://doi.org/10.1093/ajcp/aqaa062
16. Beltramo, G., Cottenet, J., Mariet, A.-S., Georges, M., Piroth, L., Tubert-Bitter, P., Bonniaud, P., & Quantin, C. (2021). Chronic respiratory diseases are predictors of severe outcome in COVID-19 hospitalised patients: A nationwide study. European Respiratory Journal, 58(6), Article 2004474. https://doi.org/10.1183/13993003.04474-2020
17. Bowerman, K. L., Rehman, S. F., Vaughan, A., Lachner, N., Budden, K. F., Kim, R.Y., Wood, D. L. A., Gellatly, S. L., Shukla, S. D., Wood, L. G., Hew, M., Chung, K. F., Adcock, I. M., Hugenholtz, P., & Hansbro, P. M. (2020). Disease-associated gut microbiome and metabolome changes in patients with chronic obstructive pulmonary disease. Nature Communications, 11, Article 5886. https://doi.org/10.1038/s41467-020-19701-w
18. Brake, S. J., Barnsley, K., Lu, W., McAlinden, K. D., Eapen, M. S., & Sohal, S. S. (2020). Smoking upregulates angiotensin-converting enzyme-2 receptor: A potential adhesion site for novel coronavirus SARS-CoV-2 (Covid-19). Journal of Clinical Medicine, 9(3), Article 841. https://doi.org/10.3390/jcm9030841
19. Brake, S. J., Eapen, M. S., McAlinden, K. D., Markos, J., Haug, G., Larby, J., Chia, C., Hardikar, A., Singhera, G. K., Hackett, T. L., & Sohal, S. S. (2022). SARS-CoV-2 (COVID-19) adhesion site protein upregulation in small airways, type 2 pneumocytes, and alveolar macrophages of smokers and COPD—Possible implications for interstitial fibrosis. International Journal of Chronic Obstructive Pulmonary Disease, 17, 101–115. https://doi.org/10.2147/COPD.S339593
20. Brar, E., Saxena, A., Dukler, C., Xu, F., Saxena, D., Cheema Brar, P., & Guo, Y. (2021). Vaping, SARS-CoV-2, and multisystem inflammatory syndrome: A perfect storm. Frontiers in Pediatrics, 9, Article 647925. https://doi.org/10.3389/fped.2021.647925
21. Budden, K. F., Gellatly, S. L., Wood, D. L. A., Cooper, M. A., Morrison, M., Hugenholtz, P., & Hansbro, P. M. (2017). Emerging pathogenic links between microbiota and the gut-lung axis. Nature Reviews Microbiology, 15(1), 55–63. https://doi.org/10.1038/nrmicro.2016.142
22. Budden, K. F., Shukla, S. D., Rehman, S. F., Bowerman, K. L., Keely, S., Hugenholtz, P., Armstrong-James, D. P. H., Adcock, I. M., Chotirmall, S. H., Chung, K. F., & Hansbro, P. M. (2019). Functional effects of the microbiota in chronic respiratory disease. The Lancet Respiratory Medicine, 7(10), 907–920. https://doi.org/10.1016/S2213-2600(18)30510-1
23. Cai, G. (2020). Bulk and single-cell transcriptomics identify tobacco-use disparity in lung gene expression of ACE2, the receptor of 2019-nCov. Life Sciences, 254, Article 117782. https://doi.org/10.1016/j.lfs.2020.117782
24. Cai, G., Bossé, Y., Xiao, F., Kheradmand, F., & Amos, C. I. (2020). Tobacco smoking increases the lung gene expression of ACE2, the receptor of SARS-CoV-2. American Journal of Respiratory and Critical Care Medicine, 201(12), 1557–1559. https://doi.org/10.1164/rccm.202003-0693LE
25. Camini, F. C., da Silva Caetano, C. C., Almeida, L. T., & de Brito Magalhães, C. L. (2017). Implications of oxidative stress on viral pathogenesis. Archives of Virology, 162(4), 907–917. https://doi.org/10.1007/s00705-016-3187-y
26. Cao, Y., Li, L., Feng, Z., Wan, S., Huang, P., Sun, X., Wen, F., Huang, X., Ning, G., & Wang, W. (2020). Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discovery, 6, Article 11. https://doi.org/10.1038/s41421-020-0147-1
27. Cariou, B., Hadjadj, S., Wargny, M., Pichelin, M., Al-Salameh, A., Allix, I., Amadou, C., Arnault, G., Baudoux, F., Bauduceau, B., Borot, S., Bourron, O., Brunet-Bourgin, A., Chaumeil, J., Chico, A., Choplin, C., Combere, M., Coustals, M., . . . CORONADO Investigators. (2020). Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: The CORONADO study. Diabetologia, 63(8), 1500–1515. https://doi.org/10.1007/s00125-020-05180-x
28. Chen, J., Jiang, Q., Xia, X., Liu, K., Yu, Z., Tao, W., Gong, W., & Han, J.-D. J. (2020). Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation. Aging Cell, 19(8), Article e13168. https://doi.org/10.1111/acel.13168
29. Chen, Y., Shan, K., & Qian, W. (2020). Asians and other races express similar levels of and share the same genetic polymorphisms of the SARS-CoV-2 cell-entry receptor. Life Sciences, 255, Article 117849. https://doi.org/10.1016/j.lfs.2020.117849
30. Choi, J. C., Jung, S.-Y., Yoon, U. A., You, S.-H., Kim, M.-S., Baek, M. S., Jung, J.-W., & Kim, W.-Y. (2020). Inhaled corticosteroids and COVID-19 risk and mortality: A nationwide cohort study. Journal of Clinical Medicine, 9(11), Article 3406. https://doi.org/10.3390/jcm9113406
31. Chotirmall, S. H., Gellatly, S. L., Budden, K. F., Mac Aogain, M., Shukla, S. D., Wood, D. L. A., Hugenholtz, P., Pethe, K., & Hansbro, P. M. (2017). Microbiomes in respiratory health and disease: An Asia-Pacific perspective. Respirology, 22(2), 240–250. https://doi.org/10.1111/resp.12969
32. Christie, M. J., Irving, A. T., Forster, S. C., Marsland, B. J., Hansbro, P. M., Hertzog, P. J., Nold-Petry, C. A., & Nold, M. F. (2021). Of bats and men: Immunomodulatory treatment options for COVID-19 guided by the immunopathology of SARS-CoV-2 infection. Science Immunology, 6(56), Article eabd0205. https://doi.org/10.1126/sciimmunol.abd0205
33. Coutard, B., Valle, C., de Lamballerie, X., Canard, B., Seidah, N. G., & Decroly, E. (2020). The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Research, 176, Article 104742. https://doi.org/10.1016/j.antiviral.2020.104742
34. Debnath, M., Banerjee, M., & Berk, M. (2020). Genetic gateways to COVID-19 infection: Implications for risk, severity, and outcomes. The FASEB Journal, 34(7), 8787–8795. https://doi.org/10.1096/fj.202001115R
35. Docherty, A. B., Harrison, E. M., Green, C. A., Hardwick, H. E., Pius, R., Norman, L., Holden, K. A., Read, J. M., Dondelinger, F., Carson, G., Mclean, K. A., Favager, A., Baillie, J. K., Openshaw, P. J. M., Semple, M. G., & ISARIC4C Investigators. (2020). Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study. BMJ, 369, Article m1985. https://doi.org/10.1136/bmj.m1985
36. Dolhnikoff, M., Duarte-Neto, A. N., de Almeida Monteiro, R. A., da Silva, L. F. F., de Oliveira, E. P., Saldiva, P. H. N., Mauad, T., & Negri, E. M. (2020). Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. Journal of Thrombosis and Haemostasis, 18(6), 1517–1519. https://doi.org/10.1111/jth.14844
37. Dreher, M., Kersten, A., Bickenbach, J., Balfanz, P., Hartmann, B., Cornelissen, C., Daher, A., Stöhr, R., Kleines, M., Lemmen, S. W., Brokmann, J. C., Müller-Wieland, D., Marx, G., & Hornef, M. (2020). The characteristics of 50 hospitalized COVID-19 patients with and without ARDS. Deutsches Ärzteblatt International, 117(16), 271–278. https://doi.org/10.3238/arztebl.2020.0271
38. Eapen, M. S., Lu, W., Hackett, T. L., Singhera, G. K., Thompson, I. E., McAlinden, K. D., Hardikar, A., Weber, H. C., Haug, G., Wark, P. A. B., & Sohal, S. S. (2021). Dysregulation of endocytic machinery and ACE2 in small airways of smokers and COPD patients can augment their susceptibility to SARS-CoV-2 (COVID-19) infections. American Journal of Physiology-Lung Cellular and Molecular Physiology, 320(1), L158–L163. https://doi.org/10.1152/ajplung.00450.2020
39. Ehrmann, S., Li, J., Ibarra-Estrada, M., Perez, Y., Pavlov, I., McNicholas, B., Roca, O., Mirza, S., Vines, D., Garcia-Salcido, R., Aguirre-Avalos, G., Trump, M. W., Nay, M.-A., Dellamonica, J., Ricard, J.-D., Messina, A., Sferrazza Papa, G. F., Sztrymf, B., . . . Awake Prone Positioning Meta-Trial Group. (2021). Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: A randomised, controlled, multinational, open-label meta-trial. The Lancet Respiratory Medicine, 9(12), 1387–1395. https://doi.org/10.1016/S2213-2600(21)00356-8
40. Fang, X., Li, S., Yu, H., Wang, P., Zhang, Y., Chen, Z., Li, Y., Cheng, L., Li, W., Jia, H., & Xaio, Y. (2020). Epidemiological, comorbidity factors with severity and prognosis of COVID-19: A systematic review and meta-analysis. Aging, 12(13), 12493–12503. https://doi.org/10.18632/aging.103579
41. Finney, L. J., Glanville, N., Farne, H., Aniscenko, J., Fenwick, P., Kemp, S. V., Trujillo-Torralbo, M.-B., Loo, S. L., Calderazzo, M. A., Wedzicha, J. A., Mallia, P., & Johnston, S. L. (2021). Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon. Journal of Allergy and Clinical Immunology, 147(2), 510–519.e5. https://doi.org/10.1016/j.jaci.2020.10.015
42. Foley, R. N., Murray, A. M., Li, S., Herzog, C. A., McBean, A. M., Eggers, P. W., & Collins, A. J. (2005). Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. Journal of the American Society of Nephrology, 16(2), 489–495. https://doi.org/10.1681/ASN.2004030203
43. Fricke-Galindo, I., & Falfán-Valencia, R. (2021). Genetics insight for COVID-19 susceptibility and severity: A review. Frontiers in Immunology, 12, Article 622176. https://doi.org/10.3389/fimmu.2021.622176
44. Gaiha, S. M., Cheng, J., & Halpern-Felsher, B. (2020). Association between youth smoking, electronic cigarette use, and COVID-19. Journal of Adolescent Health, 67(4), 519–523. https://doi.org/10.1016/j.jadohealth.2020.07.002
45. Garg, S., Kim, L., Whitaker, M., O’Halloran, A., Cummings, C., Holstein, R., Prill, M., Chai, S. J., Kirley, P. D., Alden, N. B., Kawasaki, B., Yousey-Hindes, K., Niccolai, L., Anderson, E. J., Openo, K. P., Weigel, A., Ryan, P., Lynfield, R., . . . Fry, A. M. (2020). Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed Coronavirus Disease 2019—COVID-NET, 14 States, March 1-30, 2020. MMWR. Morbidity and Mortality Weekly Report, 69(15), 458–464. https://doi.org/10.15585/mmwr.mm6915e3
46. Gattinoni, L., Chiumello, D., Caironi, P., Busana, M., Romitti, F., Brazzi, L., & Camporota, L. (2020). COVID-19 pneumonia: Different respiratory treatments for different phenotypes? Intensive Care Medicine, 46(6), 1099–1102. https://doi.org/10.1007/s00134-020-06033-2
47. Gattinoni, L., Coppola, S., Cressoni, M., Busana, M., Rossi, S., & Chiumello, D. (2020). COVID-19 does not lead to a “typical” acute respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine, 201(10), 1299–1300. https://doi.org/10.1164/rccm.202003-0817LE
48. Gerayeli, F. V., Milne, S., Cheung, C., Li, X., Yang, C. W. T., Tam, A., Choi, L. H., Bae, A., & Sin, D. D. (2021). COPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysis. EClinicalMedicine, 33, Article 100789. https://doi.org/10.1016/j.eclinm.2021.100789
49. Girardin, J.-L., Seixas, A., Ramos Cejudo, J., Osorio, R. S., Avirappattu, G., Reid, M., & Parthasarathy, S. (2021). Contribution of pulmonary diseases to COVID-19 mortality in a diverse urban community of New York. Chronic Respiratory Disease, 18, Article 1479973120986806. https://doi.org/10.1177/1479973120986806
50. Gold, J. A. W., Wong, K. K., Szablewski, C. M., Patel, P. R., Rossow, J., da Silva, J., Natarajan, P., Morris, S. B., Fanfair, R. N., Rogers-Brown, J., Verma, S., McMorrow, M. L., Schrag, S. J., Park, M. M., Drenzek, C., & Tate, J. E. (2020). Characteristics and clinical outcomes of adult patients hospitalized with COVID-19—Georgia, March 2020. MMWR. Morbidity and Mortality Weekly Report, 69(18), 545–550. https://doi.org/10.15585/mmwr.mm6918e2
51. Gorse, G. J., O’Connor, T. Z., Hall, S. L., Vitale, J. N., & Nichol, K. L. (2009). Human coronavirus and acute respiratory illness in older adults with chronic obstructive pulmonary disease. The Journal of Infectious Diseases, 199(6), 847–857. https://doi.org/10.1086/597122
52. Guan, W.-J., Liang, W.-H., Shi, Y., Gan, L.-X., Wang, H.-B., He, J.-X., & Zhong, N.-S. (2021). Chronic respiratory diseases and the outcomes of COVID-19: A nationwide retrospective cohort study of 39,420 cases. The Journal of Allergy and Clinical Immunology: In Practice, 9(7), 2645–2655.e14. https://doi.org/10.1016/j.jaip.2021.04.037
53. Guan, W.-J., Liang, W.-H., Zhao, Y., Liang, H.-R., Chen, Z.-S., Li, Y.-M., Liu, X.-Q., Chen, R.-C., Tang, C.-L., Wang, T., Ou, C.-Q., Li, L., Chen, P.-Y., Sang, L., Wang, W., Li, J.-D., Li, C.-C., Ou, L.-M., . . . He, J.-X. (2020). Comorbidity and its impact on 1590 patients with COVID-19 in China: A nationwide analysis. European Respiratory Journal, 55(5), Article 2000547. https://doi.org/10.1183/13993003.00547-2020
54. Gudbjartsson, D. F., Helgason, A., Jonsson, H., Magnusson, O. T., Melsted, P., Norddahl, G. L., Saemundsdottir, J., Sigurdsson, A., Sulem, P., Agustsdottir, A. B., Eiriksdottir, B., Fridriksdottir, R., Gardarsdottir, E. E., Georgsson, G., Gretarsdottir, S., Gudmundsson, K. R., Gudnason, T. R., Gylfason, A., . . . Stefansson, K. (2020). Spread of SARS-CoV-2 in the Icelandic population. New England Journal of Medicine, 382(24), 2302–2315. https://doi.org/10.1056/NEJMoa2006100
55. Halpin, D. M. G., Singh, D., & Hadfield, R. M. (2020). Inhaled corticosteroids and COVID-19: A systematic review and clinical perspective. European Respiratory Journal, 55(5), Article 2001009. https://doi.org/10.1183/13993003.01009-2020
56. Hansen, E. S. H., Moeller, A. L., Backer, V., Andersen, M. P., Kober, L., Kragholm, K., & Torp-Pedersen, C. (2021). Severe outcomes of COVID-19 among patients with COPD and asthma. ERJ Open Research, 7(1), 00594–02020. https://doi.org/10.1183/23120541.00594-2020
57. Haq, I. U., Krukiewicz, K., Tayyab, H., Khan, I., Khan, M., Yahya, G., & Cavalu, S. (2023). Molecular understanding of ACE-2 and HLA-conferred differential susceptibility to COVID-19: Host-directed insights opening new windows in COVID-19 therapeutics. Journal of Clinical Medicine, 12(7), Article 2645. https://doi.org/10.3390/jcm12072645
58. Herr, C., Beisswenger, C., Hess, C., Kandler, K., Suttorp, N., Welte, T., Schroeder, J.-M., Vogelmeier, C., Bals, R., & CAPNETZ Study Group. (2009). Suppression of pulmonary innate host defence in smokers. Thorax, 64(2), 144–149. https://doi.org/10.1136/thx.2008.102681
59. Higham, A., Mathioudakis, A., Vestbo, J., & Singh, D. (2020). COVID-19 and COPD: A narrative review of the basic science and clinical outcomes. European Respiratory Review, 29(158), Article 200199. https://doi.org/10.1183/16000617.0199-2020
60. Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., Müller, M. A., Drosten, C., & Pöhlmann, S. (2020). SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 181(2), 271–280.e8. https://doi.org/10.1016/j.cell.2020.02.052
61. Hou, Y. J., Okuda, K., Edwards, C. E., Martinez, D. R., Asakura, T., Dinnon, K. H., Kato, T., Lee, R. E., Yount, B. L., Mascenik, T. M., Edwards, G., Sentandreu, L. H., Asakura, E., Gilmore, R. C., Connelly, S. A., Smith, B. N., Rockx, B., . . . Baric, R. S. (2020). SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. Cell, 182(2), 429–446.e14. https://doi.org/10.1016/j.cell.2020.05.042
62. Hsu, A. C.-Y., Dua, K., Starkey, M. R., Haw, T.-J., Nair, P. M., Nichol, K., Zammit, N., Grey, S. T., Baines, K. J., Foster, P. S., & Hansbro, P. M. (2017). MicroRNA-125a and -b inhibit A20 and MAVS to promote inflammation and impair antiviral response in COPD. JCI Insight, 2(4), Article e90443. https://doi.org/10.1172/jci.insight.90443
63. Hsu, A. C.-Y., Starkey, M. R., Hanish, I., Parsons, K., Haw, T. J., Howland, L. J., Barr, I., Mahony, J. B., Foster, P. S., Knight, D. A., & Hansbro, P. M. (2015). Targeting PI3K-p110α suppresses influenza virus infection in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine, 191(9), 1012–1023. https://doi.org/10.1164/rccm.201501-0188OC
64. Hu, W., Dong, M., Xiong, M., Zhao, D., Zhao, Y., Wang, M., Wang, T., Liu, Z., Lu, L., & Hu, K. (2020). Clinical courses and outcomes of patients with chronic obstructive pulmonary disease during the COVID-19 epidemic in Hubei, China. International Journal of Chronic Obstructive Pulmonary Disease, 15, 2237–2248. https://doi.org/10.2147/COPD.S261250
65. Johansen, M. D., Irving, A., Montagutelli, X., Tate, M. D., Rudloff, I., Nold, M. F., Hansbro, N. G., Kim, R. Y., Donovan, C., Liu, G., . . . Hansbro, P. M. (2020). Animal and translational models of SARS-CoV-2 infection and COVID-19. Mucosal Immunology, 13(6), 877–891. https://doi.org/10.1038/s41385-020-00340-z
66. Johansen, M. D., Mahbub, R. M., Idrees, S., Nguyen, D. H., Miemczyk, S., Pathinayake, P., Nichol, K., Hansbro, N. G., Gearing, L. J., Hertzog, P. J., Wark, P. A., Sohal, S. S., & Hansbro, P. M. (2022). Increased SARS-CoV-2 infection, protease, and inflammatory responses in chronic obstructive pulmonary disease primary bronchial epithelial cells defined with single-cell RNA sequencing. American Journal of Respiratory and Critical Care Medicine, 206(6), 712–729. https://doi.org/10.1164/rccm.202108-1918OC
67. Jones, B., Donovan, C., Liu, G., Gomez, H. M., Chimankar, V., Harrison, C. L., Wiegman, C. H., Adcock, I. M., Knight, D. A., Hirota, J. A., & Hansbro, P. M. (2017). Animal models of COPD: What do they tell us? Animal models of COPD. Respirology, 22(1), 21–32. https://doi.org/10.1111/resp.12908
68. Kalyanaraman Marcello, R., Dolle, J., Grami, S., Adule, R., Li, Z., Tatem, K., Anyaogu, C., Apfelroth, S., Ayinla, R., Boma, N., Boutin-Foster, C., & Goldberg, E. M. (2020). Characteristics and outcomes of COVID-19 patients in New York City’s public hospital system. PLoS ONE, 15(12), Article e0243027. https://doi.org/10.1371/journal.pone.0243027
69. Kasahara, Y., Tuder, R. M., Cool, C. D., Lynch, D. A., Flores, S. C., & Voelkel, N. F. (2001). Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. American Journal of Respiratory and Critical Care Medicine, 163(3), 737–744. https://doi.org/10.1164/ajrccm.163.3.2002117
70. Kedzierski, L., Tate, M. D., Hsu, A. C., Kolesnik, T. B., Linossi, E. M., Dagley, L., Dong, Z., Freeman, S., Infusini, G., Starkey, M. R., Bird, N. L., Chatfield, S. M., Babon, J. J., Huntington, N., Mitchell, C., Rice, G., Nicholson, S. E., Hansbro, P. M., & Nicola, N. A. (2017). Suppressor of cytokine signaling (SOCS)5 ameliorates influenza infection via inhibition of EGFR signaling. eLife, 6, Article e20444. https://doi.org/10.7554/eLife.20444
71. Kumari, P., Singh, A., Ngasainao, M. R., Shakeel, I., Kumar, S., Lal, S., Singhal, A., Sohal, S. S., Singh, I. K., & Hassan, M. I. (2020). Potential diagnostics and therapeutic approaches in COVID-19. Clinica Chimica Acta, 510, 488–497. https://doi.org/10.1016/j.cca.2020.08.013
72. Lee, S. C., Son, K. J., Han, C. H., Park, S. C., & Jung, J. Y. (2021). Impact of COPD on COVID-19 prognosis: A nationwide population-based study in South Korea. Scientific Reports, 11, Article 3735. https://doi.org/10.1038/s41598-021-83226-9
73. Leung, J. M., Tiew, P. Y., Mac Aogáin, M., Budden, K. F., Yong, V. F. L., Thomas, S. S., Pethe, K., Hansbro, P. M., & Chotirmall, S. H. (2017). The role of acute and chronic respiratory colonization and infections in the pathogenesis of COPD. Respirology, 22(4), 634–650. https://doi.org/10.1111/resp.13031
74. Leung, J. M., Yang, C. X., Tam, A., Shaipanich, T., Hackett, T.-L., Singhera, G. K., Dorscheid, D. R., & Sin, D. D. (2020). ACE-2 expression in the small airway epithelia of smokers and COPD patients: Implications for COVID-19. European Respiratory Journal, 55(5), Article 2000688. https://doi.org/10.1183/13993003.00688-2020
75. Li, X., & Ma, X. (2020). Acute respiratory failure in COVID-19: Is it “typical” ARDS? Critical Care, 24, Article 198. https://doi.org/10.1186/s13054-020-02911-9
76. Li, X., Xu, S., Yu, M., Wang, K., Tao, Y., Zhou, Y., Shi, J., Zhou, M., Wu, B., Yang, Z., Zhang, C., & Yue, J. (2020). Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. Journal of Allergy and Clinical Immunology, 146(1), 110–118. https://doi.org/10.1016/j.jaci.2020.04.006
77. Lian, J., Jin, X., Hao, S., Cai, H., Zhang, S., Zheng, L., Jia, H., Hu, J., Gao, J., Zhang, Y., Zhang, X., Yu, G., Wang, X., Gu, J., Ye, C., Jin, C., Lu, Y., Yu, X., Yu, J., . . . Yang, Y. (2020). Analysis of epidemiological and clinical features in older patients with Coronavirus Disease 2019 (COVID-19) outside Wuhan. Clinical Infectious Diseases, 71(15), 740–747. https://doi.org/10.1093/cid/ciaa242
78. Liao, S.-Y., Petrache, I., Fingerlin, T. E., & Maier, L. A. (2021). Association of inhaled and systemic corticosteroid use with Coronavirus Disease 2019 (COVID-19) test positivity in patients with chronic pulmonary diseases. Respiratory Medicine, 176, Article 106275. https://doi.org/10.1016/j.rmed.2020.106275
79. Linden, D., Guo-Parke, H., Coyle, P. V., Fairley, D., McAuley, D. F., Taggart, C. C., & Kidney, J. (2019). Respiratory viral infection: A potential “missing link” in the pathogenesis of COPD. European Respiratory Review, 28(151), Article 180063. https://doi.org/10.1183/16000617.0063-2018
80. Liu, K., Fang, Y.-Y., Deng, Y., Liu, W., Wang, M.-F., Ma, J.-P., Xiao, W., Wang, Y.-N., Zhong, M.-H., Li, C.-H., Li, G.-C., & Liu, H.-G. (2020). Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chinese Medical Journal, 133(9), 1025–1031. https://doi.org/10.1097/CM9.0000000000000744
81. Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., Bi, Y., Ma, X., Zhan, F., Wang, L., Hu, T., Zhou, H., Hu, Z., Zhou, W., . . . Tan, W. (2020). Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. The Lancet, 395(10224), 565–574. https://doi.org/10.1016/S0140-6736(20)30251-8
82. Mallia, P., Message, S. D., Gielen, V., Contoli, M., Gray, K., Kebadze, T., Aniscenko, J., Laza-Stanca, V., Edwards, M. R., Slater, L., Papi, A., & Johnston, S. L. (2011). Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. American Journal of Respiratory and Critical Care Medicine, 183(6), 734–742. https://doi.org/10.1164/rccm.201006-0833OC
83. Marçalo, R., Neto, S., Pinheiro, M., Rodrigues, A. J., Sousa, N., Santos, M. A. S., Simão, P., Valente, C., Andrade, L., Marques, A., Bugalho, A., & Moura, C. S. (2022). Evaluation of the genetic risk for COVID-19 outcomes in COPD and differences among worldwide populations. PLoS ONE, 17(3), Article e0264009. https://doi.org/10.1371/journal.pone.0264009
84. Marron, R. M., Zheng, M., Fernandez Romero, G., Zhao, H., Patel, R., Leopold, I., Thomas, A., Standiford, T., Kumaran, M., Patlakh, N., Gaughan, J. P., & Criner, G. J. (2021). Impact of chronic obstructive pulmonary disease and emphysema on outcomes of hospitalized patients with Coronavirus Disease 2019 pneumonia. Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation, 8(2), 255–268. https://doi.org/10.15326/jcopdf.2020.0191
85. Marso, S. P., McGuire, D. K., Zinman, B., Poulter, N. R., Emerson, S. S., Pieber, T. R., Pratley, R. E., Haahr, H., Lange, M., Brown-Frandsen, K., Moses, A., Skibsted, S., & DEVOTE Study Group. (2017). Efficacy and safety of degludec versus glargine in type 2 diabetes. New England Journal of Medicine, 377(8), 723–732. https://doi.org/10.1056/NEJMoa161569
86. McAlinden, K. D., Barnsley, K., Weber, H. C., Haug, G., Chia, C., Eapen, M. S., & Sohal, S. S. (2021). Cochrane review update leaves big questions unanswered regarding vaping: Implications for medical practitioners. European Respiratory Journal, 57(4), Article 2100022. https://doi.org/10.1183/13993003.00022-2100
87. McAlinden, K. D., Lu, W., Eapen, M. S., & Sohal, S. S. (2021). Electronic cigarettes: Modern instruments for toxic lung delivery and posing risk for the development of chronic disease. The International Journal of Biochemistry & Cell Biology, 137, Article 106039. https://doi.org/10.1016/j.biocel.2021.106039
88. McAlinden, K. D., Lu, W., Ferdowsi, P. V., Myers, S., Markos, J., Larby, J., Chia, C., Weber, H. C., Haug, G., Eapen, M. S., & Sohal, S. S. (2021). Electronic cigarette aerosol is cytotoxic and increases ACE2 expression on human airway epithelial cells: Implications for SARS-CoV-2 (COVID-19). Journal of Clinical Medicine, 10(5), Article 1028. https://doi.org/10.3390/jcm10051028
89. Milne, S., Yang, C. X., Timens, W., Bossé, Y., & Sin, D. D. (2020). SARS-CoV-2 receptor ACE2 gene expression and RAAS inhibitors. The Lancet Respiratory Medicine, 8(6), e50–e51. https://doi.org/10.1016/S2213-2600(20)30224-1
90. Minakata, Y., Nakanishi, M., Hirano, T., Matsunaga, K., Yamagata, T., & Ichinose, M. (2005). Microvascular hyperpermeability in COPD airways. Thorax, 60(10), 882. https://doi.org/10.1136/thx.2005.041699
91. Morales, D. R., & Ali, S. N. (2021). COVID-19 and disparities affecting ethnic minorities. The Lancet, 397(10286), 1684–1685. https://doi.org/10.1016/S0140-6736(21)00949-X
92. O’Driscoll, B. R., Howard, L. S., Earis, J., Mak, V., British Thoracic Society Emergency Oxygen Guideline Group, & BTS Emergency Oxygen Guideline Development Group. (2017). BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax, 72(Suppl. 1), ii1–ii90. https://doi.org/10.1136/thoraxjnl-2017-210458
93. Ortiz-Fernández, L., & Sawalha, A. H. (2020). Genetic variability in the expression of the SARS-CoV-2 host cell entry factors across populations. Genes & Immunity, 21(4), 269–272. https://doi.org/10.1038/s41435-020-0107-7
94. Peters, M. C., Sajuthi, S., Deford, P., Christenson, S., Rios, C. L., Montgomery, M. T., Woodruff, P. G., Mauger, D. T., Erzurum, S. C., Johansson, M. W., Schiebler, M. L., Evans, C. M., Sorkness, C. A., Wenzel, S. E., Israel, E., Jarjour, N. N., Levy, B. D., Fahy, J. V., . . . Seibold, M. A. (2020). COVID-19–related genes in sputum cells in asthma: Relationship to demographic features and corticosteroids. American Journal of Respiratory and Critical Care Medicine, 202(1), 83–90. https://doi.org/10.1164/rccm.202003-0821OC
95. Pouwels, S. D., Van Den Berge, M., Vasse, G. F., Timens, W., Brandsma, C.-A., Aliee, H., Hiemstra, P. S., Guryev, V., & Faiz, A. (2023). Smoking increases expression of the SARS-CoV-2 spike protein-binding long ACE2 isoform in bronchial epithelium. Respiratory Research, 24, Article 130. https://doi.org/10.1186/s12931-023-02436-x
96. Pranata, R., Soeroto, A. Y., Huang, I., Lim, M. A., Santoso, P., Permana, H., & Lukito, A. A. (2020). Effect of chronic obstructive pulmonary disease and smoking on the outcome of COVID-19. The International Journal of Tuberculosis and Lung Disease, 24(8), 838–843. https://doi.org/10.5588/ijtld.20.0278
97. Ramakrishnan, S., Nicolau, D. V., Langford, B., Mahdi, M., Jeffers, H., Mwasuku, C., Krassowska, K., Fox, R., Binnian, I., Glover, V., Brightling, C., de Bono, S., Innes, F.-E., Lasserson, D., Gallagher, S., & Bafadhel, M. (2021). Inhaled budesonide in the treatment of early COVID-19 (STOIC): A phase 2, open-label, randomised controlled trial. The Lancet Respiratory Medicine, 9(7), 763–772. https://doi.org/10.1016/S2213-2600(21)00160-0
98. Reidel, B., Radicioni, G., Clapp, P. W., Ford, A. A., Abdelwahab, S., Rebuli, M. E., Haridass, P., Alexis, N. E., Jaspers, I., & Kesimer, M. (2018). E-cigarette use causes a unique innate immune response in the lung, involving increased neutrophilic activation and altered mucin secretion. American Journal of Respiratory and Critical Care Medicine, 197(4), 492–501. https://doi.org/10.1164/rccm.201708-1590OC
99. Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., McGinn, T., Davidson, K. W., Barnaby, D. P., Becker, L. B., Chelico, J. D., Northwell COVID-19 Research Consortium, & Choi, J. J. (2020). Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA, 323(20), 2052–2059. https://doi.org/10.1001/jama.2020.6775
100. Rouby, J. J., Martin De Lassale, E., Poete, P., Nicolas, M. H., Bodin, L., Jarlier, V., Le Charpentier, Y., Grosset, J., & Viars, P. (1992). Nosocomial bronchopneumonia in the critically ill: Histologic and bacteriologic aspects. American Review of Respiratory Disease, 146(4), 1059–1066. https://doi.org/10.1164/ajrccm/146.4.1059
101. Russo, P., Bonassi, S., Giacconi, R., Malavolta, M., Tomino, C., & Maggi, F. (2020). COVID-19 and smoking: Is nicotine the hidden link? European Respiratory Journal, 55(6), Article 2001116. https://doi.org/10.1183/13993003.01116-2020
102. Schultze, A., Walker, A. J., MacKenna, B., Morton, C. E., Bhaskaran, K., Brown, J. P., Rentsch, C. T., Williamson, E., Drysdale, H., Croker, R., Bacon, S., Humphreys, G., Defew-Marlar, H., Mehrkar, A., Eggo, R. M., Evans, S. J. W., Schmidt, S. A., . . . Goldacre, B. (2020). Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: An observational cohort study using the OpenSAFELY platform. The Lancet Respiratory Medicine, 8(11), 1106–1120. https://doi.org/10.1016/S2213-2600(20)30415-7
103. Seemungal, T. A. R., Donaldson, G. C., Bhowmik, A., Jeffries, D. J., & Wedzicha, J. A. (2000). Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine, 161(5), 1608–1613. https://doi.org/10.1164/ajrccm.161.5.9908022
104. Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach, A., & Li, F. (2020). Structural basis of receptor recognition by SARS-CoV-2. Nature, 581(7807), 221–224. https://doi.org/10.1038/s41586-020-2179-y
105. Smith, J. C., Sausville, E. L., Girish, V., Yuan, M. L., Vasudevan, A., John, K. M., & Sheltzer, J. M. (2020). Cigarette smoke exposure and inflammatory signaling increase the expression of the SARS-CoV-2 receptor ACE2 in the respiratory tract. Developmental Cell, 53(5), 514–529.e3. https://doi.org/10.1016/j.devcel.2020.05.012
106. Starkey, M. R., Jarnicki, A. G., Essilfie, A.-T., Gellatly, S. L., Kim, R. Y., Brown, A. C., Foster, P. S., Horvat, J. C., & Hansbro, P. M. (2013). Murine models of infectious exacerbations of airway inflammation. Current Opinion in Pharmacology, 13(3), 337–344. https://doi.org/10.1016/j.coph.2013.03.003
107. Vaidyula, V. R., Criner, G. J., Grabianowski, C., & Rao, A. K. (2009). Circulating tissue factor procoagulant activity is elevated in stable moderate to severe chronic obstructive pulmonary disease. Thrombosis Research, 124(2), 259–261. https://doi.org/10.1016/j.thromres.2009.01.002
108. Varga, Z., Flammer, A. J., Steiger, P., Haberecker, M., Andermatt, R., Zinkernagel, A. S., Mehra, M. R., Schuepbach, R. A., Ruschitzka, F., & Moch, H. (2020). Endothelial cell infection and endotheliitis in COVID-19. The Lancet, 395(10234), 1417–1418. https://doi.org/10.1016/S0140-6736(20)30937-5
109. Viniol, C., & Vogelmeier, C. F. (2018). Exacerbations of COPD. European Respiratory Review, 27(147), Article 170103. https://doi.org/10.1183/16000617.0103-2017
110. Wang, L., He, W., Yu, X., Hu, D., Bao, M., Liu, H., Zhou, J., & Jiang, H. (2020). Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up. Journal of Infection, 80(6), 639–645. https://doi.org/10.1016/j.jinf.2020.03.019
111. Wark, P. A. B., Pathinayake, P. S., Kaiko, G., Nichol, K., Ali, A., Chen, L., Sutanto, E. N., Garratt, L. W., Sohal, S. S., Lu, W., & Hansbro, P. M. (2021). ACE2 expression is elevated in airway epithelial cells from older and male healthy individuals but reduced in asthma. Respirology, 26(5), 442–451. https://doi.org/10.1111/resp.14021
112. Zeberg, H., & Pääbo, S. (2020). The major genetic risk factor for severe COVID-19 is inherited from Neanderthals. Nature, 587(7835), 610–612. https://doi.org/10.1038/s41586-020-2818-3
113. Zhang, J.-J., Cao, Y.-Y., Dong, X., Wang, B.-C., Liao, M.-Y., Lin, J., Yan, Y.-Q., Akdis, C. A., & Gao, Y.-D. (2020). Distinct characteristics of COVID-19 patients with initial rRT-PCR-positive and rRT-PCR-negative results for SARS-CoV-2. Allergy, 75(7), 1809–1812. https://doi.org/10.1111/all.14316
114. Zhang, J.-J., Dong, X., Cao, Y.-Y., Yuan, Y.-D., Yang, Y.-B., Yan, Y.-Q., Akdis, C. A., & Gao, Y.-D. (2020). Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy, 75(7), 1730–1741. https://doi.org/10.1111/all.14238
115. Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., Guan, L., Wei, Y., Li, H., Wu, X., Xu, J., Tu, S., Zhang, Y., . . . Cao, B. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. The Lancet, 395(10229), 1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3
116. Zhou, Y., Xu, J., Hou, Y., Leverenz, J. B., Kallianpur, A., Mehra, R., Liu, Y., Yu, H., Pieper, A. A., Jehi, L., & Cheng, F. (2021). Network medicine links SARS-CoV-2/COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment. Alzheimer’s Research & Therapy, 13, Article 110. https://doi.org/10.1186/s13195-021-00850-3
117. Zhou, Z., Ren, L., Zhang, L., Zhong, J., Xiao, Y., Jia, Z., Guo, L., Yang, J., Wang, C., Jiang, S., Yang, D., Zhang, G., Li, H., Chen, F., Xu, Y., Jin, Q., Pang, X., & Wang, J. (2020). Heightened innate immune responses in the respiratory tract of COVID-19 patients. Cell Host & Microbe, 27(6), 883–890.e2. https://doi.org/10.1016/j.chom.2020.04.017
118. Connolly, B.; Perkins, G.D.; Ji, C.; Couper, K.; Lall, R.; Baillie, J.K.; Bradley, J.M.; Dark, P.; Dave, C.; De Soyza, A.; et al. RCT Abstract—An Adaptive Randomized Controlled Trial of Non-Invasive Respiratory Strategies in Acute Respiratory Failure Patients with COVID-19. In Proceedings of the Respiratory Infections and Bronchiectasis; European Respiratory Society, 2021; p. RCT4271. Available online: http://erj.ersjournals.com/lookup/doi/10.1183/13993003.congress-2021.RCT4271 (accessed on 24 February 2022).
119. Bertaina, M.; Nuñez-Gil, I.J.; Franchin, L.; Fernández Rozas, I.; Arroyo-Espliguero, R.; Viana-Llamas, M.C.; Romero, R.; Maroun Eid, C.; Uribarri, A.; Becerra-Muñoz, V.M.; et al. Non-invasive ventilation for SARS-CoV-2 acute respiratory failure: A subanalysis from the HOPE COVID-19 registry. Emerg. Med. J. EMJ 2021, 38, 359–365. [Google Scholar] [CrossRef]
120. Grieco, D.L.; Menga, L.S.; Cesarano, M.; Rosà, T.; Spadaro, S.; Bitondo, M.M.; Montomoli, J.; Falò, G.; Tonetti, T.; Cutuli, S.L.; et al. Effect of Helmet Noninvasive Ventilation vs. High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients with COVID-19 and Moderate to Severe Hypoxemic Respiratory Failure: The HENIVOT Randomized Clinical Trial. JAMA 2021, 325, 1731. [Google Scholar] [CrossRef]
121. Simons, S.O.; Hurst, J.R.; Miravitlles, M.; Franssen, F.M.E.; Janssen, D.J.A.; Papi, A.; Duiverman, M.L.; Kerstjens, H.A.M. Caring for patients with COPD and COVID-19: A viewpoint to spark discussion. Thorax 2020, 75, 1035–1039. [Google Scholar] [CrossRef]
122. Wilson, N.M.; Marks, G.B.; Eckhardt, A.; Clarke, A.M.; Young, F.P.; Garden, F.L.; Stewart, W.; Cook, T.M.; Tovey, E.R. The effect of respiratory activity, non-invasive respiratory support and facemasks on aerosol generation and its relevance to COVID-19. Anaesthesia 2021, 76, 1465–1474. [Google Scholar] [CrossRef] [PubMed]
123. Nalbandian, A.; Sehgal, K.; Gupta, A.; Madhavan, M.V.; McGroder, C.; Stevens, J.S.; Cook, J.R.; Nordvig, A.S.; Shalev, D.; Sehrawat, T.S.; et al. Post-acute COVID-19 syndrome. Nat. Med. 2021, 27, 601–615. [Google Scholar] [CrossRef] [PubMed]
124. Greenhalgh, T.; Knight, M.; A’Court, C.; Buxton, M.; Husain, L. Management of post-acute covid-19 in primary care. BMJ 2020, 370, m3026. [Google Scholar] [CrossRef] [PubMed]
125. Shah, W.; Hillman, T.; Playford, E.D.; Hishmeh, L. Managing the long term effects of covid-19: Summary of NICE, SIGN, and RCGP rapid guideline. BMJ 2021, 372, n136. [Google Scholar] [CrossRef]
126. Halpin, D.M.G.; Decramer, M.; Celli, B.; Kesten, S.; Liu, D.; Tashkin, D.P. Exacerbation frequency and course of COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2012, 7, 653–661. [Google Scholar] [CrossRef]
127. Soler-Cataluña, J.J.; Martínez-García, M.A.; Román Sánchez, P.; Salcedo, E.; Navarro, M.; Ochando, R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005, 60, 925–931. [Google Scholar] [CrossRef]
128. Bafadhel, M.; McKenna, S.; Terry, S.; Mistry, V.; Reid, C.; Haldar, P.; McCormick, M.; Haldar, K.; Kebadze, T.; Duvoix, A.; et al. Acute exacerbations of chronic obstructive pulmonary disease: Identification of biologic clusters and their biomarkers. Am. J. Respir. Crit. Care Med. 2011, 184, 662–671. [Google Scholar] [CrossRef]
129. George, S.N.; Garcha, D.S.; Mackay, A.J.; Patel, A.R.C.; Singh, R.; Sapsford, R.J.; Donaldson, G.C.; Wedzicha, J.A. Human rhinovirus infection during naturally occurring COPD exacerbations. Eur. Respir. J. 2014, 44, 87–96. [Google Scholar] [CrossRef]
130. Mathioudakis, A.G.; Janssens, W.; Sivapalan, P.; Singanayagam, A.; Dransfield, M.T.; Jensen, J.-U.S.; Vestbo, J. Acute exacerbations of chronic obstructive pulmonary disease: In search of diagnostic biomarkers and treatable traits. Thorax 2020, 75, 520–527. [Google Scholar] [CrossRef]
131. Wilkinson, T.M.A.; Hurst, J.R.; Perera, W.R.; Wilks, M.; Donaldson, G.C.; Wedzicha, J.A. Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest 2006, 129, 317–324. [Google Scholar] [CrossRef]
132. Global Initiative for Chronic Obstructive Lung Disease. Available online: https://goldcopd.org (accessed on 10 March 2022).
133. Xu, J.; Xu, X.; Jiang, L.; Dua, K.; Hansbro, P.M.; Liu, G. SARS-CoV-2 induces transcriptional signatures in human lung epithelial cells that promote lung fibrosis. Respir. Res. 2020, 21, 182. [Google Scholar] [CrossRef]
134. Hopkinson, N.S.; Molyneux, A.; Pink, J.; Harrisingh, M.C. Guideline Committee (GC) Chronic obstructive pulmonary disease: Diagnosis and management: Summary of updated NICE guidance. BMJ 2019, 366, l4486. [Google Scholar] [CrossRef]
135. Rawson, T.M.; Moore, L.S.P.; Zhu, N.; Ranganathan, N.; Skolimowska, K.; Gilchrist, M.; Satta, G.; Cooke, G.; Holmes, A. Bacterial and Fungal Coinfection in Individuals with Coronavirus: A Rapid Review to Support COVID-19 Antimicrobial Prescribing. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2020, 71, 2459–2468. [Google Scholar] [CrossRef]
136. Living Guidance for Clinical Management of COVID-19. Available online: https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-2 (accessed on 10 March 2022).
137. Boixeda, R.; Rabella, N.; Sauca, G.; Delgado, M.; Martínez-Costa, X.; Mauri, M.; Vicente, V.; Palomera, E.; Serra-Prat, M.; Capdevila, J.A. Microbiological study of patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease (AE-COPD) and the usefulness of analytical and clinical parameters in its identification (VIRAE study). Int. J. Chron. Obstruct. Pulmon. Dis. 2012, 327. [Google Scholar] [CrossRef]
138. van Geffen, W.H.; Douma, W.R.; Slebos, D.J.; Kerstjens, H.A.M. Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD. Cochrane Database Syst. Rev. 2016, CD011826. [Google Scholar] [CrossRef]
139. Rossi, A. Long-acting β2-agonists (LABA) in chronic obstructive pulmonary disease: Efficacy and safety. Int. J. Chron. Obstruct. Pulmon. Dis. 2008, 3, 521–529. [Google Scholar] [CrossRef]
140. Ceravolo, M.G.; Arienti, C.; de Sire, A.; Andrenelli, E.; Negrini, F.; Lazzarini, S.G.; Patrini, M.; Negrini, S. International Multiprofessional Steering Committee of Cochrane Rehabilitation REH-COVER action Rehabilitation and COVID-19: The Cochrane Rehabilitation 2020 rapid living systematic review. Eur. J. Phys. Rehabil. Med. 2020, 56, 642–651. [Google Scholar] [CrossRef]
141. de Sire, A.; Andrenelli, E.; Negrini, F.; Negrini, S.; Ceravolo, M.G. Systematic rapid living review on rehabilitation needs due to COVID-19: Update as of April 30th, 2020. Eur. J. Phys. Rehabil. Med. 2020, 56, 354–360. [Google Scholar] [CrossRef]
142. Curci, C.; Pisano, F.; Bonacci, E.; Camozzi, D.M.; Ceravolo, C.; Bergonzi, R.; De Franceschi, S.; Moro, P.; Guarnieri, R.; Ferrillo, M.; et al. Early rehabilitation in post-acute COVID-19 patients: Data from an Italian COVID-19 Rehabilitation Unit and proposal of a treatment protocol. Eur. J. Phys. Rehabil. Med. 2020, 56, 633–641. [Google Scholar] [CrossRef]
143. Ferraro, F.; Calafiore, D.; Dambruoso, F.; Guidarini, S.; de Sire, A. COVID-19 related fatigue: Which role for rehabilitation in post-COVID-19 patients? A case series. J. Med. Virol. 2021, 93, 1896–1899. [Google Scholar] [CrossRef]
144. Salawu, A.; Green, A.; Crooks, M.G.; Brixey, N.; Ross, D.H.; Sivan, M. A Proposal for Multidisciplinary Tele-Rehabilitation in the Assessment and Rehabilitation of COVID-19 Survivors. Int. J. Environ. Res. Public Health 2020, 17, 4890. [Google Scholar] [CrossRef]
145. McCarthy, B.; Casey, D.; Devane, D.; Murphy, K.; Murphy, E.; Lacasse, Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2015, CD003793. [Google Scholar] [CrossRef] [PubMed]
146. COVID-19 Emergency Declaration Blanket Waivers for Health Care Providers. 44. Available online: https://www.cms.gov/files/document/summary-covid-19-emergency-declaration-waivers.pdf (accessed on 25 February 2022).
147. Impact of COVID-19 on the Physical Therapy Profession. Available online: https://www.naranet.org/uploads/userfiles/files/documents/APTAReportImpactOfCOVID-19OnThePhysicalTherapyProfession.pdf (accessed on 25 February 2022).
148. Dechman, G.; Aceron, R.; Beauchamp, M.; Bhutani, M.; Bourbeau, J.; Brooks, D.; Goldstein, R.; Goodridge, D.; Hernandez, P.; Janaudis-Ferreira, T.; et al. Delivering pulmonary rehabilitation during the COVID-19 pandemic: A Canadian Thoracic Society position statement. Can. J. Respir. Crit. Care Sleep Med. 2020, 4, 232–235. [Google Scholar] [CrossRef]
149. Garvey, C.; Singer, J.P.; Bruun, A.M.; Soong, A.; Rigler, J.; Hays, S. Moving Pulmonary Rehabilitation into the Home: A CLINICAL REVIEW. J. Cardiopulm. Rehabil. Prev. 2018, 38, 8–16. [Google Scholar] [CrossRef] [PubMed]
150. Gonzalez-Gerez, J.J.; Bernal-Utrera, C.; Anarte-Lazo, E.; Garcia-Vidal, J.A.; Botella-Rico, J.M.; Rodriguez-Blanco, C. Therapeutic pulmonary telerehabilitation protocol for patients affected by COVID-19, confined to their homes: Study protocol for a randomized controlled trial. Trials 2020, 21, 588. [Google Scholar] [CrossRef]
151. Lippi, G.; Henry, B.M. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). Respir. Med. 2020, 167, 105941. [Google Scholar] [CrossRef]
152. Zhao, Q.; Meng, M.; Kumar, R.; Wu, Y.; Huang, J.; Lian, N.; Deng, Y.; Lin, S. The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis. J. Med. Virol. 2020, 92, 1915–1921. [Google Scholar] [CrossRef]
153. Ambrosino, N.; Fracchia, C. The role of tele-medicine in patients with respiratory diseases. Expert Rev. Respir. Med. 2017, 11, 893–900. [Google Scholar] [CrossRef]
154. Bentley, C.L.; Powell, L.; Potter, S.; Parker, J.; Mountain, G.A.; Bartlett, Y.K.; Farwer, J.; O’Connor, C.; Burns, J.; Cresswell, R.L.; et al. The Use of a Smartphone App and an Activity Tracker to Promote Physical Activity in the Management of Chronic Obstructive Pulmonary Disease: Randomized Controlled Feasibility Study. JMIR MHealth UHealth 2020, 8, e16203. [Google Scholar] [CrossRef]
155. Bierman, R.T.; Kwong, M.W.; Calouro, C. State Occupational and Physical Therapy Telehealth Laws and Regulations: A 50-State Survey. Int. J. Telerehabilitation 2018, 10, 3–54. [Google Scholar] [CrossRef]
156. Tsutsui, M.; Gerayeli, F.; Sin, D.D. Pulmonary Rehabilitation in a Post-COVID-19 World: Telerehabilitation as a New Standard in Patients with COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2021, 16, 379–391. [Google Scholar] [CrossRef]
157. Dougherty, K.; Mannell, M.; Naqvi, O.; Matson, D.; Stone, J. SARS-CoV-2 B.1.617.2 (Delta) Variant COVID-19 Outbreak Associated with a Gymnastics Facility—Oklahoma, April-May 2021. MMWR Morb. Mortal. Wkly. Rep. 2021, 70, 1004–1007. [Google Scholar] [CrossRef]
158. Baden, L.R.; El Sahly, H.M.; Essink, B.; Kotloff, K.; Frey, S.; Novak, R.; Diemert, D.; Spector, S.A.; Rouphael, N.; Creech, C.B.; et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021, 384, 403–416. [Google Scholar] [CrossRef]
159. Candelli, M.; Pignataro, G.; Torelli, E.; Gullì, A.; Nista, E.C.; Petrucci, M.; Saviano, A.; Marchesini, D.; Covino, M.; Ojetti, V.; et al. Effect of influenza vaccine on COVID-19 mortality: A retrospective study. Intern. Emerg. Med. 2021, 16, 1849–1855. [Google Scholar] [CrossRef]
160. Wilcox, C.R.; Islam, N.; Dambha-Miller, H. Association between influenza vaccination and hospitalisation or all-cause mortality in people with COVID-19: A retrospective cohort study. BMJ Open Respir. Res. 2021, 8, e000857. [Google Scholar] [CrossRef]
161. Angelopoulou, A.; Alexandris, N.; Konstantinou, E.; Mesiakaris, K.; Zanidis, C.; Farsalinos, K.; Poulas, K. Imiquimod—A toll like receptor 7 agonist—Is an ideal option for management of COVID 19. Environ. Res. 2020, 188, 109858. [Google Scholar] [CrossRef]
162. Pedote, P.D.; Termite, S.; Gigliobianco, A.; Lopalco, P.L.; Bianchi, F.P. Influenza Vaccination and Health Outcomes in COVID-19 Patients: A Retrospective Cohort Study. Vaccines 2021, 9, 358. [Google Scholar] [CrossRef]
163. Berghaus, T.M.; Karschnia, P.; Haberl, S.; Schwaiblmair, M. Disproportionate decline in admissions for exacerbated COPD during the COVID-19 pandemic. Respir. Med. 2022, 191, 106120. [Google Scholar] [CrossRef]
164. Tan, J.Y.; Conceicao, E.P.; Wee, L.E.; Sim, X.Y.J.; Venkatachalam, I. COVID-19 public health measures: A reduction in hospital admissions for COPD exacerbations. Thorax 2021, 76, 512–513. [Google Scholar] [CrossRef]
165. Liang, Y.; Chang, C.; Chen, Y.; Dong, F.; Zhang, L.; Sun, Y. Symptoms, Management and Healthcare Utilization of COPD Patients During the COVID-19 Epidemic in Beijing. Int. J. Chron. Obstruct. Pulmon. Dis. 2020, 15, 2487–2494. [Google Scholar] [CrossRef]
166. Pleguezuelos, E.; Del Carmen, A.; Moreno, E.; Ortega, P.; Vila, X.; Ovejero, L.; Serra-Prat, M.; Palomera, E.; Garnacho-Castaño, M.V.; Loeb, E.; et al. The Experience of COPD Patients in Lockdown Due to the COVID-19 Pandemic. Int. J. Chron. Obstruct. Pulmon. Dis. 2020, 15, 2621–2627. [Google Scholar] [CrossRef] [PubMed]
167. Global Initiative for Chronic Obstructive Lung Disease. Remote COPD Patient Follow-Up during COVID-19 Pandemic Restrictions. Available online: https://goldcopd.org/remote-copd-patient-follow-up-during-covid-19-pandemic-restrictions/#:~:text=During%20the%20COVID%2D19%20pandemic,be%20necessary%20for%20some%20time (accessed on 10 March 2022).